Perfluorodecanoic acid

Synonyms: 十九氟癸酸; PFDA
Perfluorodecanoic acid (PFDA) 是一种具有口服活性的全氟烷基物质,可通过内质网应激介导的脂质成分改变导致大鼠胎儿睾丸间质细胞功能障碍,并通过诱导内质网应激降低大鼠 R2C 睾丸间质细胞中的睾酮生物合成,可用于胎儿睾丸间质细胞功能异常的相关研究。
产品编号: MS-X46416 纯度: 98.0% CAS No.: 335-76-2 分子式: C10Hf19O2 分子量: 514.08
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Perfluorodecanoic acid (PFDA) 是一种具有口服活性的全氟烷基物质,可通过内质网应激介导的脂质成分改变导致大鼠胎儿睾丸间质细胞功能障碍,并通过诱导内质网应激降低大鼠 R2C 睾丸间质细胞中的睾酮生物合成,可用于胎儿睾丸间质细胞功能异常的相关研究。

生物实验数据

生物活性 Perfluorodecanoic acid (PFDA) is an orally active perfluoroalkyl substance that induces rat fetal Leydig cell dysfunction through endoplasmic reticulum stress-mediated alterations in lipid composition and reduces testosterone biosynthesis in rat R2C Leydig cells by inducing endoplasmic reticulum stress, and can be used in research related to fetal Leydig cell dysfunction.
IC50 & Target

Caspase-1

 

Caspase 3

 

Caspase-7

 

IL-1β

 

体外研究
(In Vitro)

Perfluorodecanoic acid (0-150 μM; 24 h) 可通过诱导内质网应激降低大鼠 R2C 睾丸间质细胞中的睾酮生物合成,其中 100 μM PFDA (24 h incubation) 会显著抑制类固醇生成,150 μM PFDA (24 h incubation) 则会降低细胞活力。

Cell Viability Assay

Cell Line: rat R2C Leydig cells
Concentration: 50-150 μM (cell viability assay); 100 μM (testosterone biosynthesis assay)
Incubation Time: 24 h (cell viability assay); 24 h (testosterone biosynthesis assay)
Result: Showed negligible impact on cell viability at concentrations up to 125 μM for 24 h.
Significantly reduced cell viability at 150 μM for 24 h.
Significantly decreased testosterone synthesis at 100 μM for 24 h.
Downregulated mRNA levels of steroidogenesis-related genes at 100 μM for 24 h.
Increased phosphorylation levels of ER stress proteins PERK and EIF2α at 100 μM for 24 h.
Reduced protein levels of steroidogenesis-related proteins including SCARB1, STAR, CYP11A1, and HSD3B1 at 100 μM for 24 h.
体内研究
(In Vivo)

Perfluorodecanoic acid (1-5 mg/kg/day; p.o.; daily; gestational day 14 to 21) 会干扰胎鼠睾丸脂质代谢,诱导内质网应激,并抑制胎鼠睾丸间质细胞功能,从而产生剂量依赖性生殖发育毒性:在 2.5 和 5 mg/kg/day 剂量下,血清睾酮水平显著降低,且出现多核生殖母细胞。
Perfluorodecanoic acid (PFDA) (0.03-32.0 mg/kg/day; p.o. [gavage]; daily; 4 consecutive days on gd 6-15) 可在 gd 6-15 日接受给药的时间交配 C57BL/6N 小鼠中引发母体毒性 (体重增长降低、肝脏重量增加) 和胚胎毒性 (活胎体重降低、最高剂量下胚胎死亡率无显著性升高、罕见轻微外部畸形),未观察到致畸作用。

Animal Model: Sprague-Dawley (56 days old; male and female dams; male neonatal pups; in utero exposure via gestational dam treatment from gestational day 14 to 21)
Dosage: 1 mg/kg/day; 2.5 mg/kg/day; 5 mg/kg/day
Administration: p.o.; daily; gestational day 14 to 21
Result: Increased male pup body weight at 1 and 2.5 mg/kg/day; decreased male pup body weight at 5 mg/kg/day.
Decreased anogenital distance at all doses.
Significantly reduced serum testosterone levels at 2.5 and 5 mg/kg/day.
Downregulated mRNA and protein levels of fetal Leydig cell genes/proteins including Lhcgr, Scarb1, Star, Cyp11a1, Hsd3b1, Cyp17a1, Insl3, and Gli1 at all doses.
Reduced fetal Leydig cell size and cytoplasmic size at all doses.
Induced multinucleated gonocyte formation in testicular cords at 2.5 and 5 mg/kg/day.
Upregulated Elovl1 mRNA and downregulated Scd2 mRNA at 5 mg/kg/day.
Increased phosphorylation of PERK and EIF2α at all doses.
Increased ATF4 protein levels at all doses; increased ATF6 and GRP78 protein levels at 2.5 and 5 mg/kg/day.
Reduced SCARB1 protein levels; increased ELOVL1 protein levels; reduced SCD2 protein levels at all doses.
Animal Model: C57BL/6N (female, 6-8 weeks of age, time-mated, gestation day 0 defined by vaginal plug observation)
Dosage: 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0 mg/kg/day
Administration: p.o. [gavage]; daily; 4 consecutive days on gd 10-13
Result: Significantly reduced maternal body weight gain.
Significantly increased absolute maternal liver weights.
Significantly increased relative maternal liver weights.
Significantly reduced live fetal body weigh.
Observed non-significant increase in fetal mortality.
Observed rare minor fetal external variations: 1 fetus with left neck hematoma.
Detected no hydronephrosis, cleft palate, or other soft tissue or skeletal malformations at any dose.
性状 固体
颜色 White to off-white

化学信息

分子量 514.08
分子式 C10Hf19O2
CAS No. 335-76-2
别名 十九氟癸酸; PFDA

储存&溶解度

储存方式

Store at room temperature, keep dry and cool

In solvent -80°C 1 year
-20°C 6 months
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 100 mg/mL (194.52 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

Ethanol 中的溶解度 : 100 mg/mL (194.52 mM; 超声助溶)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / Ethanol1 mM1.9452 mL9.7261 mL19.4522 mL48.6306 mL
5 mM0.3890 mL1.9452 mL3.8904 mL9.7261 mL
10 mM0.1945 mL0.9726 mL1.9452 mL4.8631 mL
15 mM0.1297 mL0.6484 mL1.2968 mL3.2420 mL
20 mM0.0973 mL0.4863 mL0.9726 mL2.4315 mL
25 mM0.0778 mL0.3890 mL0.7781 mL1.9452 mL
30 mM0.0648 mL0.3242 mL0.6484 mL1.6210 mL
40 mM0.0486 mL0.2432 mL0.4863 mL1.2158 mL
50 mM0.0389 mL0.1945 mL0.3890 mL0.9726 mL
60 mM0.0324 mL0.1621 mL0.3242 mL0.8105 mL
80 mM0.0243 mL0.1216 mL0.2432 mL0.6079 mL
100 mM0.0195 mL0.0973 mL0.1945 mL0.4863 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础